Rankings
▼
Calendar
EOLS Q4 2025 Earnings — Evolus, Inc. Revenue & Financial Results | Market Cap Arena
EOLS
Evolus, Inc.
$353M
Q4 2025 Earnings
Healthcare
Drug Manufacturers - Specialty & Generic
Income Statement
Revenue
$88M
+11.6% YoY
Gross Profit
$59M
67.3% margin
Operating Income
$4M
4.8% margin
Net Income
$130,000
0.1% margin
EPS (Diluted)
$0.01
QoQ Revenue Growth
+27.7%
Cash Flow
Operating Cash Flow
$0
Free Cash Flow
$0
Stock-Based Comp.
$0
Balance Sheet
Total Assets
$226M
Total Liabilities
$249M
Stockholders' Equity
-$23M
Cash & Equivalents
$54M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$88M
$79M
+11.6%
Gross Profit
$59M
$50M
+17.8%
Operating Income
$4M
-$2M
+282.4%
Net Income
$130,000
-$7M
+101.9%
Revenue Segments
Product
$89M
99%
Service
$1M
1%
← FY 2025
All Quarters